C12N 2760/18562
By genetic engineering
Official title: by genetic engineering
C12N2760/18562 (By genetic engineering) appears on 39 US grants and 54 published applications in this corpus.
Search patents in C12N- Granted patents
- 39
- Published applications
- 54
- Assignees
- 38
- Inventors
- 68
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 2 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 2 | 3 |
| 2015 | 1 | 7 |
| 2016 | 0 | 2 |
| 2017 | 5 | 3 |
| 2018 | 3 | 6 |
| 2019 | 3 | 5 |
| 2020 | 5 | 4 |
| 2021 | 3 | 3 |
| 2022 | 7 | 3 |
| 2023 | 0 | 5 |
| 2024 | 3 | 2 |
| 2025 | 4 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modified RSV F proteins and methods of their use15 Jul 2025US 12,357,684 B2
- Chimeric RSV, immunogenic compositions, and methods of use25 Mar 2025US 12,257,296 B2Emory University
- Methods and compositions for treating negative-sense single-stranded RNA virus18 Feb 2025US 12,227,769 B2Nationwide Children's Hospital, Inc.
- Recombinant RSV with silent mutations, vaccines, and methods related thereto7 Jan 2025US 12,186,386 B2Emory University and Children's Healthcare of Atlanta, Inc.
- Modulation of replicative fitness by deoptimization of synonymous codons17 Sep 2024US 12,090,197 B2The Government of the USA, as represented by the Secretary, Department of Health and Human Services
- RSV Vaccines with Truncated G-Protein Mucin Domains30 Apr 2026US 2026/0115274 A1Butler University
- Methods and compositions for treating negative-sense single-stranded rna virus7 Aug 2025US 2025/0250548 A1Nationwide Children's Hospital, Inc.
- Multivalent vaccine for paramyxoviruses and uses thereof22 May 2025US 2025/0161436 A1Icosavax, Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization19 Dec 2024US 2024/0417699 A1The Research Foundation for The State University of New York
- Method of eliciting an immune response against respiratory syncytial virus23 May 2024US 2024/0165217 A1Codagenix Inc.
Most cited
By later US patents
- Modified RSV F proteins and methods of their use23US 10,022,437 B2Novavax, Inc. · 2018
- Modified RSV F proteins and methods of their use20US 8,715,692 B2Novavax, Inc. · 2014
- Modulation of replicative fitness by deoptimization of synonymous codons20US 8,846,051 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2014
- Modified RSV F proteins and methods of their use11US 9,675,685 B2Novavax, Inc. · 2017
- Respiratory syncytial virus with a genomic deficiency complemented in trans7US 9,107,939 B2De Staat der Nederlanden, vert. door de minister van VWS · 2015